_targeting the MAPK Pathway in KRAS-Driven Tumors
- PMID: 32289276
- DOI: 10.1016/j.ccell.2020.03.013
_targeting the MAPK Pathway in KRAS-Driven Tumors
Abstract
KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been approved to treat these tumors. Despite the recent development of drugs that block KRASG12C, the majority of KRAS oncoproteins remain undruggable. Here, we review recent efforts to validate individual components of the mitogen-activated protein kinase (MAPK) pathway as _targets to treat KRAS-mutant cancers by comparing genetic information derived from experimental mouse models of KRAS-driven lung and pancreatic tumors with the outcome of selective MAPK inhibitors in clinical trials. We also review the potential of RAF1 as a key _target to block KRAS-mutant cancers.
Keywords: KRAS-driven cancer; MAPK pathway; clinical trials; lung adenocarcinoma; pancreatic ductal adenocarcinoma.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
An integrative pharmacogenomics analysis identifies therapeutic _targets in KRAS-mutant lung cancer.EBioMedicine. 2019 Nov;49:106-117. doi: 10.1016/j.ebiom.2019.10.012. Epub 2019 Oct 23. EBioMedicine. 2019. PMID: 31668570 Free PMC article.
-
_targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.Adv Cancer Res. 2022;153:101-130. doi: 10.1016/bs.acr.2021.07.008. Epub 2021 Sep 2. Adv Cancer Res. 2022. PMID: 35101228
-
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.Cancer Res. 2007 May 15;67(10):4933-9. doi: 10.1158/0008-5472.CAN-06-4592. Cancer Res. 2007. PMID: 17510423
-
_targeting KRAS mutant lung cancer: light at the end of the tunnel.Mol Oncol. 2022 Mar;16(5):1057-1071. doi: 10.1002/1878-0261.13168. Epub 2022 Jan 18. Mol Oncol. 2022. PMID: 34951114 Free PMC article. Review.
-
_targeting Krasg12c -mutant cancer with a mutation-specific inhibitor.J Intern Med. 2020 Aug;288(2):183-191. doi: 10.1111/joim.13057. Epub 2020 Apr 7. J Intern Med. 2020. PMID: 32176377 Review.
Cited by
-
Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study.Front Immunol. 2024 Jan 10;14:1203459. doi: 10.3389/fimmu.2023.1203459. eCollection 2023. Front Immunol. 2024. PMID: 38268915 Free PMC article.
-
SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers.Nat Commun. 2024 Sep 12;15(1):8002. doi: 10.1038/s41467-024-52326-1. Nat Commun. 2024. PMID: 39266533 Free PMC article.
-
_targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.Transl Lung Cancer Res. 2023 Feb 28;12(2):346-368. doi: 10.21037/tlcr-22-639. Epub 2023 Feb 20. Transl Lung Cancer Res. 2023. PMID: 36895930 Free PMC article. Review.
-
Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRASG12C Inhibitors.Pharmaceuticals (Basel). 2022 May 8;15(5):584. doi: 10.3390/ph15050584. Pharmaceuticals (Basel). 2022. PMID: 35631410 Free PMC article.
-
The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer.Cancers (Basel). 2021 Oct 6;13(19):5004. doi: 10.3390/cancers13195004. Cancers (Basel). 2021. PMID: 34638488 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous
